Since expanded γδT cells retain the capacity to secrete pro-inflammatory cytokines (IFNγ, TNFα) and to express, albeit at reduced levels, lymph node-homing markers (CCR7, CD62L), the infusion of tumor-antigen-loaded γδT cells may be followed by a single treatment with zoledronate. Here, CCR7 is linked to neoplasm.